Most current treatments focus on managing symptoms instead of restoring lost function. As a result, many patients adapt to permanent impairments rather than regain independence. This gap between survival and real functional recovery remains one of the most urgent problems in modern medicine. Closing it requires more than incremental improvements. It demands therapies that actively support regeneration and restore function.

The post How NurExone Biologic Advances Regenerative Nanodrugs for CNS Injuries Led by Dr. Lior Shaltiel appeared first on NurExone.

Exosomes are small extracellular vesicles released by cells and involved in intercellular communication. They contain proteins, lipids and nucleic acids, and their composition reflects both their cellular origin and the biological conditions under which they are produced. These properties have made them attractive for a range of applications, particularly as potential therapeutic delivery vehicles and as biologically active components of regenerative products. They can also be engineered or loaded with defined therapeutic cargo, including RNA-based molecules.

READ MORE >>>

The post Exosomes Move Toward the Mainstream. Manufacturing May Be the Key to Scale appeared first on NurExone.

NurExone is pursuing a modular approach that enables manufacturing capacity to expand by adding standardized production units in parallel (scaling out approach), rather than engineering larger bioreactor vessels (scaling up approach). This strategy has the potential to protect capital investments, accelerate development timelines, and allow production to match commercial demand, subject to successful validation and implementation.

READ MORE >>>

The post NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth appeared first on NurExone.

TORONTO and HAIFA, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced new preclinical findings demonstrating the therapeutic benefits of its naïve exosomes (exosomes without added therapeutic cargo) and lead pharmaceutical drug candidate ExoPTEN in optic nerve injury models. The studies were conducted in collaboration with Prof. Ygal Rotenstreich’s team at the Goldschleger Eye Institute at Sheba Medical Center. The new data supports the advancement of the Company’s optic nerve injury program into larger-animal studies, including a planned rabbit model, marking a key milestone toward potential human clinical evaluation.

READ MORE >>>

The post NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results appeared first on NurExone.

As part of the Company’s business development and stakeholder-engagement activities in the U.S., Chief Executive Officer Dr. Lior Shaltiel will actively participate as speaker in three conference programs and attend the invitation-only World Medical Innovation Forum. R&D Director Dr. Tali Kizhner will also represent the Company as a speaker at the 8^th Exosome-Based Therapeutics Development Summit.

READ MORE >>>

The post NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update appeared first on NurExone.

Annual General and Special Meeting Results

Capitalized terms used but not otherwise defined in this press release have the meanings ascribed to them in the Company’s management information circular dated August 10, 2026 (the “Circular”). Additional information regarding the Consolidation is contained in the Circular and the Company’s press release dated August 21, 2026.

READ MORE >>>

The post NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update appeared first on NurExone.

NurExone’s exosomes are designed to act as biological delivery vehicles, targeting damaged tissue either on their own or carrying therapeutic cargo. NanoPass’s FDA-cleared MicronJet™ intradermal delivery platform provides precise, controlled and safe placement at the site of administration (leveraging advanced MEMS technology silicon-crystal pyramids).

READ MORE >>>

The post NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications appeared first on NurExone.

The Company’s full set of unaudited condensed interim consolidated financial statements for the six months ended June 30, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.

READ MORE >>>

The post NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results appeared first on NurExone.

Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential clinical development, we are also taking steps intended to support the manufacturing and commercial capabilities that may be required for the Company’s longer-term development,” said Mr. Drucker. “We look forward to participating in the Moody Capital Solutions conference and engaging with members of the investment community. The conference will provide an opportunity to discuss the Company’s therapeutic-development activities, exosome platform and U.S. manufacturing and commercial initiatives with members of the investment community.”

READ MORE >>>

The post NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference appeared first on NurExone.